Compare Cassava Sciences Inc (FLNA) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while First Trust NASDAQ 100 Technology Index Fund trades at $333 (market cap $4.10B). The key difference: First Trust NASDAQ 100 Technology Index Fund is far larger — about 104.1× Cassava Sciences Inc's market cap, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and First Trust NASDAQ 100 Technology Index Fund for 40 Days on average.
| FLNA | QTEC | |
|---|---|---|
Market Cap | $39.40M | $4.10B |
Volume | 759,018 | 264,303 |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $340.28 |
52-Week Low | $0.68 | $207.03 |
Typical Hold Time | 37 Days | 40 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
QTEC trades at $335.82, down 1.31% today, with a bullish technical signal from moving averages but bearish oscillators. The ETF provides equal-weighted exposure to NASDAQ-100 technology stocks, offering diversification across software and hardware sectors. Recent analysis highlights software industry undervaluation relative to historical averages, positioning QTEC as a liquid alternative to similar funds.
The outlook remains cautiously optimistic given technology sector growth potential, though overbought RSI levels suggest near-term consolidation. Key risks include sector volatility and macroeconomic pressures on tech valuations, while institutional interest supports long-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
